Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Tuesday, June 30

ORAL SESOS 1500970 15.00-7.009

B26 ART II: Clinical Trials
Chairs: Brian G.Gazzard,Vanessa Johnson
Venue: Arena
Time: 15.00-17.00
286 Combination abacavir (1592, ABC)/Amprenavir (141W94) 12204
therapy in HIV-1 infected antiretroviral naive subjects with
CD4+ counts 400 cells/μl and viral load 5000 copies/ml
Pierre-Alexandre Bart*; G.P. Rizzardi; S. Gallant; P. Meylan;
W. Spreen; H. McDade; U.K. Pantaleo, Switzerland
287 Hydroxyurea in combination regimens for the treatment 12235
ofantiretroviral naive, HIV-infected adults
Sergio Lupo*; Marianne E. Federici; P Cahn; I. Cassetti;
R. Pedro; G. Ruiz-Palacios;J.S.G. Montaner; T. Kelleher, USA
288 Salvage of multi-drug resistant HIV-infection with 12205
D4T/3TC/hydroxyurea
Steven Miles*; R.E. Winters; P. Ruane, USA
289 Assessment of viral load and CD4/CD8 ratio in blood and 41142
lymph nodes in patients treated with d4T,ddl~ hydroxyurea (HU)
Sabine Yerly*; 0. Rutschmann; F Marchal; M. Opravil;
B. Hirschel; L. Perrin, Switzerland
290 Study of protease inhibitor combination in Europe (SPICE): 12222
saquinavir soft gelatin capsule (SQV-SGC) plus nelfinavir
(NFV) in HIV-infected individuals
GraemeMoyle, UK
291 Treatment of ritonavir (RTV)/saquinavir (SQV) versus 12274
RTV/SQV/Stavudine (d4T) (The Prometheus Study):
Preliminary results
Elisabeth H. Gisolf*; F. de WolfJ. Pelgrom; F. van Wanzeele;

C28 Mobile Populations and HIV: Vulnerability, Risk Q
and Human Rights
Chairs: Mary Haour-Knipe, RobertTezzo
Venue: Session Hall VI
Time: 15.00-17.00
303 HIV and human mobility: an epidemiological overview
AlixAdrien
304 War, refugees and HIV
MillicentObaso
305 Mobile populations and risk situations in Mexico and
Central America
Mario Bronfman
306 Mobile populations and risk situations in Southeast Asia
Irene Fernandez
307 Labour migration and HIV epidemics in Africa
Joseph Decosas
308 Human rights issues
Norbert Gilmore
309 Human rights issues from the point of view of migration
activists
Reda Sadki
D25 Mother-to-Child HIV Transmission: 0 0
Infant Feeding
Chairs: Eric Mercier, Catherine Oyuge
Venue: Session Hall I
Time: 15.00-17.00
310 Breastfeeding programmes and HIV questions
FelicitySavage-King
311 ICW Reproductive Project
Lindy Francis
312 Psychosocial aspects of breastfeeding
Linda Richter

JUNE

M. Popescu; A. Japour; S.A. Danner; R. van Leeuwen,
The Netherlands
292 Long-term evaluation of saquinavir-soft-gel-capsule or
indinavir as part of combination triple therapy (CHEESE Study)
Jan Borleffs*; Charles A.B. Boucher, The Netherlands
293 The safety, tolerance, pharmacokinetics, and efficacy of
PNU-140690,a new non-peptidic HIV protease inhibitor,
in a phase 1/11 study
Yenyun Wang*; CM. Tutton; M. T. Borin; CL. Daenzer; H. Li;
R.M. Wurtz;A.A. Piergies; W. W. Freimuth, USA

12267
41176

313 Breast feeding in the HIV/AIDS era in Zimbabwe
Caroline Maposhere, Zimbabwe
314 Attitudes and behaviour of HIV-infected women on infant feeding

44266

C27 Bridging Session: Vaccines: Overcoming 0
Obstacles to Human Trials
Chairs: Seth Berkley, Jose Esparza
Venue: Session Hall V
Time: 15.00-17.00
294 Introduction
Jose Esparza
295 Overview of trials underway and planned
Carole Heilman
296 Ethics of vaccine research and development
Ruth Macklin

Glenda Gray
315 Strategies for preserving breastfeeding
Mary Bassett
316 Breast or bottle? A cost-effectiveness evaluation of formula 24124
feeding for the prevention of postnatal transmission of HIV
in an urban South African setting
Neil Soderlund*; G.E. Gray; K.J. Zwi, South Africa
317 Discussant
Catherine Peckham
NOTES

297 Trials in developing countries
Natth Bhamarapravati
298 Community involvement and mobilisation
Ronaldo Mussauer de Lima
299 The role of industry
Jean-Jaques Bertrand
300 The economics of AIDS vaccines and prevention
Callisto Madavo
301 Closing statement
Seth Berkley
302 Questions from the floor
Pathway Symbols: Human Rights O Policy 0 Youth and Children
CONFERENCE WORKBOOK

73